EUVIMEDEUVIMED entdecken
Crossref

How PBPK Can Help to Understand Old Drugs and Inform their Dosing in Elderly: Amantadine Case Study

Olha Shuklinova iD, Sibylle Neuhoff iD, Sebastian Polak iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3276 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Olha Shuklinova und 2 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, Kraków, Poland. Hauptthemen laut MEDLINE: Amantadine, Models, Biological. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amantadine, despite being on the market for 55 years, has several unknown aspects of its pharmacokinetics especially related to the influence of covariates such as age, disease, or interactions linked to amantadine's renal elimination. As amantadine is used in Parkinson's disease and is considered a potential candidate in COVID treatment and other diseases, there is an unmet need for thorough understanding of its pharmacokinetic in special populations, such as the elderly. We aimed to mechanistically describe amantadine pharmacokinetics in healthy subjects and shed some light on the differences in drug behavior between healthy volunteers (18–65 years) and an elderly/geriatric population (65–98 years) using PBPK modeling and simulation. The middle‐out PBPK model includes mechanistic description of drug renal elimination, specifically an organic cation transporter (OCT)2‐mediated electrogenic bidirectional transport (basolateral) and multidrug and toxic compound extrusion (MATE)1‐mediated efflux (apical). The model performance was verified against plasma and urine data reported after single and multiple dose administration in healthy volunteers and elderly patients from 18 independent studies. The ratios of predicted vs. observed maximal plasma concentration and area under the concentration–time curve values were within 1.25‐fold. The model illustrates that renal transporter activity is expected to decrease in healthy elderly compared to healthy volunteers, which is in line with literature proteomic data for OCT2. The model was applied to assess the potential of reaching toxicity‐related plasma concentrations in different age groups of geriatric subjects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmantadineModels, BiologicalHumansAgedAdultMiddle AgedAged, 80 and overMaleYoung AdultAdolescentFemaleOrganic Cation Transporter 2Renal EliminationOrganic Cation Transport ProteinsCOVID-19 Drug TreatmentAge FactorsHealthy VolunteersComputer Simulation

Substanzen

AmantadineOrganic Cation Transporter 2Organic Cation Transport ProteinsSLC22A2 protein, human

Autor:innen und Institutionen

  • Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, Kraków, Poland.
  • Simcyp Division, Certara UK Limited, Sheffield, UK.
  • Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland.

ORCID-Profile: Olha Shuklinova, Sibylle Neuhoff, Sebastian Polak

Zitieren

APA

Shuklinova, O., Neuhoff, S., & Polak, S. (2024). How PBPK Can Help to Understand Old Drugs and Inform their Dosing in Elderly: Amantadine Case Study. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3276

Vancouver

Shuklinova O, Neuhoff S, Polak S. How PBPK Can Help to Understand Old Drugs and Inform their Dosing in Elderly: Amantadine Case Study. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3276

BibTeX
@article{Shuklinova2024,
  author = {Shuklinova, Olha and Neuhoff, Sibylle and Polak, Sebastian},
  title = {How PBPK Can Help to Understand Old Drugs and Inform their Dosing in Elderly: Amantadine Case Study},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3276}
}
Kostenlos starten →